AtriCure (ATRC) vs LeMaitre Vascular (LMAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed LeMaitre Vascular (LMAT) over the past year, gaining 56.2% versus a loss of 8.6%. Over five years, LMAT leads with a +48.0% price change compared with -25.3% for ATRC. AtriCure is the larger company by market cap ($2.69 billion vs $1.82 billion), about 1.5 times the size.
On valuation, LeMaitre Vascular trades at a lower forward P/E (25.1x vs 121.8x for AtriCure). LeMaitre Vascular pays a dividend yielding 1.13%, while AtriCure does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | LMAT |
|---|---|---|
| Share price | $52.84 | $79.64 |
| Market cap | $2.69B | $1.82B |
| 1-day change | -0.88% | +0.42% |
| YTD return | +34.76% | -2.21% |
| 1-year return | +56.24% | -8.62% |
| 5-year return | -25.30% | +48.02% |
| P/E ratio (TTM) | 251.62 | 27.94 |
| Forward P/E | 121.76 | 25.05 |
| EPS (TTM) | $0.21 | $2.85 |
| Dividend yield | 0.00% | 1.13% |
| Annual dividend | $0.00 | $0.90 |
| Revenue (latest FY) | $534.53M | — |
| Revenue growth (YoY) | +14.88% | — |
| Net income (latest FY) | $-11.45M | — |
| Gross margin | 74.98% | — |
| Operating margin | -1.77% | — |
| Net margin | -2.14% | — |
| 52-week high | $61.70 | $118.01 |
| 52-week low | $25.36 | $78.22 |
| Distance from 52-week high | -14.36% | -32.51% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +3.88% | +34.35% |
| Average volume | 1.09M | 328.65K |
| Shares outstanding | 50.87M | 22.87M |
| Employees | 1,350 | 646 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed LMAT by 64.9 percentage points over the past year.
- AtriCure trades at a higher earnings multiple (251.6x vs 27.9x trailing P/E).
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.13% vs 0.00%).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 646 employees
ATRC vs LMAT FAQ
Which is bigger, AtriCure or LeMaitre Vascular?
AtriCure (ATRC) is larger, with a market capitalization of $2.69B compared with $1.82B for LeMaitre Vascular (LMAT).
Which stock has performed better over the past year, ATRC or LMAT?
ATRC returned +56.24% over the past 12 months, compared with -8.62% for LMAT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATRC or LMAT?
LMAT has the lower trailing P/E at 27.9, versus 251.6 for ATRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AtriCure or LeMaitre Vascular?
LeMaitre Vascular pays a dividend yielding 1.13%, while AtriCure does not currently pay a regular dividend.
Are AtriCure and LeMaitre Vascular in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.